Klivira
Request demo

Streamlining PointClickCare Prior Authorization for Rheumatology

Klivira streamlines PointClickCare prior authorization for rheumatology, automating the complex process for high-cost biologics and infusion therapies within long-term care and senior living facilities.

Rheumatology practices within long-term care (LTC) and skilled nursing facilities (SNFs) face significant prior authorization challenges, particularly for advanced biologic and targeted therapies. These PAs are critical for patient access but often strain administrative resources. Klivira integrates with PointClickCare to transform this workflow, ensuring timely approvals and reduced administrative overhead for rheumatology services.

The Intersection of PointClickCare and Rheumatology PA Demands

PointClickCare (PCC) is a dominant EMR in long-term care and senior living, serving a population often managing chronic autoimmune conditions that require advanced rheumatology treatments. The high volume of prior authorizations for biologics and infusion therapies in rheumatology, combined with the administrative workflows inherent to LTC settings, necessitates a robust solution for managing these critical approvals within the PCC ecosystem.

High-Volume PA Categories in Rheumatology

  • TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab)
  • Non-TNF biologics and targeted synthetic DMARDs (e.g., IL-6, IL-17, IL-23 inhibitors, JAK inhibitors)
  • Specialty drugs for specific indications (e.g., anifrolumab for SLE, belimumab for SLE)
  • Advanced imaging for inflammatory arthritis assessment and DEXA scans for osteoporosis management
  • Infusion therapy administration for biologics and other injectables

Klivira's Integration with PointClickCare for Rheumatology Workflows

Klivira leverages PointClickCare APIs to embed prior authorization automation directly into existing clinical and administrative workflows. This integration allows rheumatology teams to initiate PA requests from within the PCC environment, pre-populating forms with patient demographics and relevant clinical data, thereby reducing manual data entry and accelerating the submission process for biologics and other high-cost therapies.

Critical Documentation for Rheumatology Prior Authorizations

  • Diagnosis documentation with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, 2019 EULAR/ACR for SLE)
  • Disease activity assessment scores (e.g., DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE)
  • Documentation of prior conventional DMARD trial and response (e.g., methotrexate, sulfasalazine)
  • Evidence of step therapy compliance, including biosimilar substitution where required by payer policy
  • Completion of pre-initiation screenings (e.g., TB, hepatitis B/C, immunization status) for immunosuppressive biologics
  • Specific justification for JAK inhibitors, often requiring prior TNF inhibitor failure due to FDA boxed warnings

Addressing Common Rheumatology PA Denials

Rheumatology practices frequently encounter denials due to issues like incomplete step therapy documentation, failure to attempt required biosimilar substitutions, or missing disease activity scores. Klivira's platform is designed with ACR-guideline-aware policy logic to flag these common pitfalls proactively, guiding staff through the necessary documentation steps before submission and reducing the incidence of avoidable denials.

Optimizing Chronic Treatment and Re-authorizations in PCC

The chronic nature of rheumatologic conditions means ongoing prior authorization burden, with periodic re-authorizations typically required every 6-12 months for biologics. Klivira's system tracks these re-authorization cycles within the PointClickCare integrated workflow, prompting for continuous documentation of disease response and ensuring timely resubmissions, minimizing treatment interruptions for patients in long-term care settings.

Frequently asked questions

How does Klivira integrate with PointClickCare for rheumatology prior authorizations?

Klivira integrates with PointClickCare via its robust APIs, enabling seamless data exchange. This allows for the pre-population of PA forms with patient data from PCC, initiation of PA requests directly from the EMR, and real-time status updates, streamlining the entire authorization lifecycle for rheumatology treatments.

Can Klivira handle the complexity of biosimilar substitution and step therapy for rheumatology drugs?

Yes, Klivira's platform incorporates sophisticated payer-policy logic that accounts for specific biosimilar substitution mandates and step therapy requirements. This ensures that rheumatology PA requests initiated through PointClickCare adhere to individual payer guidelines, minimizing denials related to incorrect drug sequencing or biosimilar selection.

Does Klivira support re-authorization workflows for chronic rheumatology conditions managed in PointClickCare?

Absolutely. Given the chronic nature of many rheumatological diseases, Klivira provides a dedicated workflow for periodic re-authorizations. It tracks authorization expiration dates, prompts for necessary continuous disease response documentation, and facilitates timely resubmission, ensuring uninterrupted access to critical therapies for patients within PointClickCare-managed facilities.

How does Klivira help reduce denials for rheumatology prior authorizations in PointClickCare?

Klivira reduces denials by enforcing adherence to payer-specific clinical criteria and documentation requirements, including ACR treatment guidelines. The system flags common denial reasons such as incomplete step therapy, missing disease activity scores, or insufficient screening documentation, guiding staff to complete all necessary information before submission from PointClickCare.

Is Klivira compatible with both medical and pharmacy benefit PAs for rheumatology biologics?

Yes, Klivira's platform is designed to manage prior authorizations across both medical and pharmacy benefits. For rheumatology biologics that can be self-administered (pharmacy benefit) or provider-administered (medical benefit), Klivira intelligently routes the PA request based on the specific drug, administration mode, and payer policy, ensuring correct submission regardless of benefit type.

Related coverage

Other point-click-care prior auth coverage

Ready to automate prior auth for this integration?

See how Klivira automates prior authorizations for your team.

Request a demo